Examine the structural reasons behind India’s dominance in generics manufacturing. Discuss the constraints in transitioning to innovation-driven pharma growth.
Kartavya Desk Staff
Topic: Changes in industrial policy and their effects on industrial growth.
Topic: Changes in industrial policy and their effects on industrial growth.
Q6. Examine the structural reasons behind India’s dominance in generics manufacturing. Discuss the constraints in transitioning to innovation-driven pharma growth. (10 M)
Difficulty Level: Medium
Reference: IE
Why the question India’s pharmaceutical sector is central to global health security and industrial policy debates, especially as the country seeks to shift from generics-led scale to innovation-led value creation. Key Demand of the question The question requires examination of the structural factors that enabled India’s dominance in generics manufacturing and discussion of the constraints hindering transition to innovation-driven pharma growth. Structure of the Answer: Introduction Briefly highlight India’s global role as a leading generics producer and the emerging need to move up the pharmaceutical value chain. Body Indicate how patent policy, cost competitiveness and manufacturing ecosystem created generics dominance. Explain how weak R&D intensity, risk capital constraints and regulatory bottlenecks limit innovation-led transformation. Conclusion Conclude by suggesting that sustained investment in science and ecosystem reforms is essential for shifting from volume-based growth to value-based pharmaceutical leadership.
Why the question India’s pharmaceutical sector is central to global health security and industrial policy debates, especially as the country seeks to shift from generics-led scale to innovation-led value creation.
Key Demand of the question The question requires examination of the structural factors that enabled India’s dominance in generics manufacturing and discussion of the constraints hindering transition to innovation-driven pharma growth.
Structure of the Answer:
Introduction Briefly highlight India’s global role as a leading generics producer and the emerging need to move up the pharmaceutical value chain.
• Indicate how patent policy, cost competitiveness and manufacturing ecosystem created generics dominance.
• Explain how weak R&D intensity, risk capital constraints and regulatory bottlenecks limit innovation-led transformation.
Conclusion Conclude by suggesting that sustained investment in science and ecosystem reforms is essential for shifting from volume-based growth to value-based pharmaceutical leadership.